Basic Information
| LncRNA/CircRNA Name | LOC100132354 |
| Synonyms | NA |
| Region | GRCh38_1:29554-31109 |
| Ensemble | |
| Refseq | NR_024478 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, RNAi, other |
| Sample | LAD tissues and cell lines (SPCA-1, A549) |
| Expression Pattern | up-regulated |
| Function Description | Survival analysis showed that VEGFA, VEGFR2, and bFGF were poor predictors, while TSP-1 was a good predictor in LAD. Knockdown or overexpression of LOC100132354 affected the expression levels of bFGF, VEGFA/VEGFR2 signaling pathway, and downstream target molecules, such as Ras, P-A-Raf, P-B-Raf, P-C-Raf, P-Mekl/2, and P-Erk1/2, while decreased TSP-1. After knockdown or overexpression of VEGFA expression, no significant changes in the expression level of LOC100132354 were found. Tumorigenesis of nude mice confirmed that LOC100132354 can significantly increase the tumor MVD. |
| Pubmed ID | 30323681 |
| Year | 2018 |
| Title | lncRNA LOC100132354 Promotes Angiogenesis Through VEGFA/VEGFR2 Signaling Pathway in Lung Adenocarcinoma |
External Links
| Links for LOC100132354 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |